A practical reference on pineal peptides: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-04 and is reviewed periodically as new material appears.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Computed for the free acid of Ala-Glu-Asp-Gly |
| Molecular mass | About 390.35 g/mol | Free peptide; salt forms shift the value |
| Appearance | White to off-white solid | Typical of short peptides after freeze-drying |
| Solubility class | Freely soluble in water | Aqueous buffers are also commonly used |
| Common synonyms | Epitalon, epithalone, AEDG | AEDG is the single-letter sequence |
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
One possibility for making the theorized long-lived nuclei of copernicium (291Cn and 293Cn) and flerovium near the middle of the island, is using even heavier targets such as 250Cm, 249Bk, 251Cf, and 254Es, that when fused with 48Ca would yield isotopes such as 291Mc and 291Fl (as decay products of 299Uue, 295Ts, and 295Lv), which may have just enough neutrons to alpha decay to nuclides close enough to the centre of the island to possibly undergo electron capture and move inward to the centre. However, reaction cross sections would be small and little is yet known about the decay properties of superheavies near the beta-stability line. This may be the current best hope to synthesize nuclei in the island of stability, but it is speculative and may or may not work in practice. Another possibility is to use controlled nuclear explosions to get the high neutron flux needed to make macroscopic amounts of such isotopes. This would mimic the r-process where the actinides were first produced in nature and the gap of instability after polonium bypassed, as it would bypass the gaps of instability at 258–260Fm and at mass number 275 (atomic numbers 104 to 108). Some such isotopes (especially 291Cn and 293Cn) may even have been synthesized in nature, but would decay far too quickly (with half-lives of only thousands of years) and be produced in far too small quantities (~10−12 the abundance of lead) to be detectable today outside cosmic rays.
Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.
==== Two-state substitution models ==== An alternative way to analyze DNA sequence data is to recode the nucleotides as purines (R) and pyrimidines (Y); this practice is often called RY-coding. Insertions and deletions in multiple sequence alignments can also be encoded as binary data and analyzed in using a two-state model. The simplest two-state model of sequence evolution is called the Cavender-Farris model or the Cavender-Farris-Neyman (CFN) model; the name of this model reflects the fact that it was described independently in several different publications. The CFN model is identical to the Jukes-Cantor model adapted to two states and it has been implemented as the "JC2" model in the popular IQ-TREE software package (using this model in IQ-TREE requires coding the data as 0 and 1 rather than R and Y; the popular PAUP* software package can interpret a data matrix comprising only R and Y as data to be analyzed using the CFN model). It is also straightforward to analyze binary data using the phylogenetic Hadamard transform. The alternative two-state model allows the equilibrium frequency parameters of R and Y (or 0 and 1) to take on values other than 0.5 by adding a single free parameter; this model is variously called CFu or GTR2 (in IQ-TREE). This issue is not too commonly encountered in nucleotide sequences, but can matter a lot for other types of binary data such as the presence or absence of a morphological innovation.
In manufacturing, the simulated moving bed (SMB) process is a highly engineered process for implementing chromatographic separation. It is used to separate one chemical compound or one class of chemical compounds from one or more other chemical compounds to provide significant quantities of the purified or enriched material at a lower cost than could be obtained using simple (batch) chromatography. It cannot provide any separation or purification that cannot be done by a simple column purification. The process is rather complicated. The single advantage which it brings to a chromatographic purification is that it allows the production of large quantities of highly purified material at a dramatically reduced cost. The cost reductions come about as a result of: the use of a smaller amount of chromatographic separation media stationary phase, a continuous and high rate of production, and decreased solvent and energy requirements. This improved economic performance is brought about by a valve-and-column arrangement that is used to lengthen the stationary phase indefinitely and allow very high solute loadings to the process. In the conventional moving bed technique of production chromatography the feed entry and the analyte recovery are simultaneous and continuous, but because of practical difficulties with a continuously moving bed, the simulated moving bed technique was proposed.
Sources: en.wikipedia.org
According to the US, in 2024, China continues to be the primary supplier of chemical precursors to Mexican drug cartels, and Chinese money launderers have become central to the global drug trade. In December 2024, a Chinese national in Chicago was sentenced to 10 years in prison laundering $62 million in drug money for Mexican traffickers involving currency swaps between United States and China, and China and Mexico. In January 2025, two former executives of a Chinese chemical company were convicted of a scheme to import fentanyl precursor chemicals into the United States. One was sentenced to 25 years in prison and the other to 15 years.
liraglutide (Victoza for type 2 diabetes, Saxenda for weight management, manufactured by Novo Nordisk), approved in 2010/2014 dulaglutide (Trulicity, manufactured by Eli Lilly), approved in 2014 semaglutide (Ozempic and Rybelsus for diabetes, Wegovy for weight management, manufactured by Novo Nordisk), approved in 2021/2019/2021 tirzepatide (a GIP analog with dual GLP-1 receptor and GIP receptor agonism; Mounjaro for diabetes, Zepbound for weight management, manufactured by Eli Lilly), approved in 2022/2024 Discontinued:
== Other organisms == Paroxetine is a common finding in wastewater. It is highly toxic to the alga Pseudokirchneriella subcapitata (syn. Raphidocelis subcapitata). It also is toxic to the soil nematode Caenorhabditis elegans. Alberca et al., 2016 found that paroxetine acts as a trypanocide against T. cruzi. Alberca et al., 2016 finds a leishmanicide effect. Alberca finds that paroxetine produces cell death of the promastigotes of L. infantum. The mechanism of action remains unknown. Various types of bacteria can break down paroxetine in the environment. These include, for example Pseudomonas sp., Bosea sp., Shewanella sp., Species of Chitinophagaceae and Acinetobacter sp.
Choose the best candidates from pre-clinical (animal) studies A 2006 analysis of studies for 1,026 therapies in stroke and theorized that the best drugs from pre-clinical studies were not the ones being brought into clinical trials. Many of the drugs with the strongest signals in pre-clinical models were not the ones later brought into clinical trials. Improve pre-clinical testing Others proposed that the lack of standardization in pre-clinical models made it difficult to select the best drugs. One attempt to address this comes from the National Institute of Neurological Disorders and Stroke which started the Stroke Preclinical Assessment Network to fund a testing regimen that will allow head-to-head comparisons of different drugs. Treat patients early enough After the onset of stroke, the amount of brain tissue that dies increases over time, leading to the saying, "Time is brain." Treating patients earlier can lead to a greater amount of brain tissue being saved. Protect the brain for long enough An element of clinical trial design that affects the probability that a truly beneficial drug will show benefit is the duration of protection. A truly effective drug that is tested in a clinical trial where it protects the brain for a longer period of time would be expected to show a greater benefit verses a placebo than the same drug in a different clinical trial where it only protects the brain for a shorter period of time.
A liver biopsy (tissue examination) is the only test widely accepted (gold standard) as definitively diagnosing and distinguishing MASLD and MASH from other forms of liver disease. It can be used to assess the severity of inflammation and resultant fibrosis. However, since most people affected by MASLD are likely to be asymptomatic, liver biopsy presents too high a risk for routine diagnosis, so other methods are preferred, such as liver ultrasonography or liver MRI. For young people, guidelines recommend liver ultrasonography, but biopsy remains the best evidence. Liver biopsy is also the gold standard to detect hepatic fibrosis and assess its progression. Routine liver function blood tests are not sensitive enough to detect MASLD, and biopsy is the only procedure that can reliably differentiate MASLD from MASH. There are several liver biopsy techniques available to obtain liver tissue. Percutaneous liver biopsy remains the most common practice. Biopsies can also be performed via the transvenous route, either during surgery or by laparoscopy, especially for people with contraindications to a percutaneous approach. The liver biopsy can also be image-guided, in real-time or not, which is recommended for some clinical situations, such as people with known liver lesions, previous intra-abdominal surgery who may have adhesions, a small liver that is difficult to percuss, people with obesity, and people with evident ascites.
Sources: en.wikipedia.org
=== Sedation === Since trazodone may impair the mental or physical abilities required for the performance of potentially hazardous tasks, such as operating an automobile or machinery, the patient should be cautioned not to engage in such activities while impaired. Compared to the reversible MAOI antidepressant drug moclobemide, more impairment of vigilance occurs with trazodone. Trazodone has been found to impair driving ability.
The Miami Herald reported on 2 October 2025 that sources said the US effort had "effectively shut down" the busy "Caribbean route" for estimated 2024 annual shipments of between 350 and 500 tons of cocaine coming from Venezuela. According to the Miami Herald, the campaign's "goal is financial: cutting off the drug revenue that sustains loyalty among Venezuela's senior military and police commanders, many of whom are accused of profiting directly from narcotrafficking." Trafficking through older air and land routes from Colombia are more costly than maritime shipments, and sources said that Venezuelan "cash flow from trafficking is under direct threat, and that puts the cohesion of the military elite at risk", with "authorities [turning] to heavier taxation and extortion of businesses to keep the state's security apparatus afloat." According to The Economist, "Few ... think drugs are the sole or even the main focus" of the operation, noting that fentanyl, the drug that causes the most deaths in the US, is almost entirely "synthesized in Mexico and trafficked north over land" and that "the hardware"—e.g. destroyers—"doesn't match the task" of drug policing.
=== Pivot to scientific instruments === HVEC had originally built products for clients in cancer therapy and industrial radiography, but its machines proved valuable for basic research. The company's proximity to MIT research gave it unique advantages in understanding accelerator requirements. Van de Graaff, Trump, and fellow board member William Buechner regularly consulted with physicists pushing the boundaries of nuclear structure studies, translating experimental needs into engineering specifications. In 1949, Brookhaven National Laboratory commissioned HVEC to build a 4 MeV Van de Graaff particle injector for its planned high-energy Cosmotron accelerator. When completed in 1953, the Cosmotron became the first accelerator to exceed billion-electronvolt potentials. HVEC's standard 2 MV accelerators also found nuclear science customers, including the Naval Research Laboratory and European universities. In 1951, HVEC adopted a Trump-designed MIT accelerator as a research accelerator prototype. This single-stage "CN" model was the first mass-produced research accelerator. CN machines operated at voltages up to 6.5 megavolts and established HVEC's reputation for reliability in nuclear research applications. In 1954, Canada's Chalk River Laboratories asked HVEC to modify the CN into higher-voltage tandem accelerator, yielding a highly profitable product line that sustained the company for fifteen years.
Inkjet (dot on demand or continuous) systems are capable of printing high resolution (300 dpi or higher for dot on demand) images at press speed (up to 1000fpm). These solutions can be deployed either on-press or off-line. Laser marking can be employed to ablate a coating or to cause a color change in certain materials. The advantage of laser is fine detail and high speed for character printing, and no consumables. Not all substrates accept a laser mark, and certain colors (e.g. red) are not suitable for barcode reading. Thermal Transfer and Direct Thermal. For lower speed off-press applications, thermal transfer and direct thermal printers are ideal for printing variable data on labels. Software systems are available for managing traceability throughout the entire production, processing, marketing and distribution system. Some of these software systems combine multiple software modules allowing the producer to capture traceability information from all farming, processing and packing activities. Others, capture data in the field and packing operations to integrate with retail buying platforms and carry data all the way to the end consumer. Leveraging new advancements in mobile technology, food brands are now incorporating mobile messaging and QR codes on product labels. Consumers can text or scan the barcode with smartphones for immediate retrieval of product information. Consumers can also trace the origins of their purchased produce at websites.
Sources: en.wikipedia.org
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.
Epitalon and epithalon both circulate, and the difference reflects transliteration of a name coined in Russian-language publications. Reference to the extract it derives from, epithalamin, explains the shared stem. Databases and suppliers are inconsistent, so a search for one spelling alone may miss relevant entries.
No. Epithalamin is a multi-component preparation obtained from pineal tissue, and its exact composition is not fully characterised. Epitalon is a single defined tetrapeptide described as a short synthetic counterpart of that extract, so the two are related in origin but not interchangeable in identity.
Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.